Search

Your search keyword '"Soverini, S."' showing total 8 results
Start Over Author "Soverini, S." Journal hemasphere
8 results on '"Soverini, S."'

1. S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS

Author

Mancini, M., primary, De Santis, S., additional, Monaldi, C., additional, Bruno, S., additional, Castagnetti, F., additional, Gugliotta, G., additional, Iurlo, A., additional, Cerrano, M., additional, Galimberti, S., additional, Balducci, S., additional, Stagno, F., additional, Rosti, G., additional, Cavo, M., additional, and Soverini, S., additional

Published
2022
Full Text
View/download PDF

2. P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS

Author

Mancini, M., primary, Monaldi, C., additional, De Santis, S., additional, Papayannidis, C., additional, Rondoni, M., additional, Sartor, C., additional, Bruno, S., additional, Curti, A., additional, Zanotti, R., additional, Bonifacio, M., additional, Scaffidi, L., additional, Pagano, L., additional, Criscuolo, M., additional, Ciceri, F., additional, Elena, C., additional, Tosi, P., additional, Valent, P., additional, Cavo, M., additional, and Soverini, S., additional

Published
2022
Full Text
View/download PDF

3. PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Author

Mancini, M., primary, Monaldi, C., additional, De Santis, S., additional, Papayannidis, C., additional, Rondoni, M., additional, Bavaro, L., additional, Martelli, M., additional, Ficarra, E., additional, Paciello, G., additional, Fontana, M.C., additional, Zanotti, R., additional, Pagano, L., additional, Albano, F., additional, Ciceri, F., additional, Elena, C., additional, Tosi, P., additional, Delledonne, M., additional, Valent, P., additional, Martinelli, G., additional, Cavo, M., additional, and Soverini, S., additional

Published
2019
Full Text
View/download PDF

4. S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Author

Mancini, M., primary, De Santis, S., additional, Monaldi, C., additional, Bavaro, L., additional, Martelli, M., additional, Castagnetti, F., additional, Gugliotta, G., additional, Rosti, G., additional, Fontana, M.C., additional, Dan, E., additional, Sinigallia, B., additional, Iurlo, A., additional, Orofino, N., additional, Abbruzzese, E., additional, Salvucci, M., additional, Pregno, P., additional, Gozzini, A., additional, Crugnola, M., additional, Albano, F., additional, Bonifacio, M., additional, Calistri, E., additional, Tiribelli, M., additional, Binotto, G., additional, Imovilli, A., additional, Trabacchi, E., additional, Galimberti, S., additional, Baratè, C., additional, Tenti, E., additional, Baccarani, M., additional, Martinelli, G., additional, Cavo, M., additional, and Soverini, S., additional

Published
2019
Full Text
View/download PDF

6. PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Soverini, S., primary, Martelli, M., additional, Bavaro, L., additional, Papayannidis, C., additional, Sica, S., additional, Sorà, F., additional, Albano, F., additional, Galimberti, S., additional, Barate’, C., additional, Rondoni, M., additional, Abruzzese, E., additional, Annunziata, M., additional, Russo, S., additional, Mannina, D., additional, Stulle, M., additional, Imovilli, A., additional, Curti, A., additional, Bonifacio, M., additional, Ferrero, D., additional, Basilico, C., additional, Reddiconto, G., additional, Mineo, G., additional, Laginestra, M.A., additional, Pileri, S.A., additional, Mignone, F., additional, Percesepe, A., additional, Martinelli, G., additional, and Cavo, M., additional

Published
2019
Full Text
View/download PDF

7. Current treatment approaches in CML

Author

Simona Soverini, Gabriele Gugliotta, Gianantonio Rosti, Michele Baccarani, Fausto Castagnetti, Castagnetti F., Gugliotta G., Soverini S., Baccarani M., and Rosti G.

Subjects
tyrosine kinase inhibitors, Treatment-free remission, CML, business.industry, Medicine, Hematology, Current (fluid), business, Reliability engineering
Abstract

Take home messages Five tyrosine kinase inhibitors are available, the treatment strategy is still challenging. Baseline risk, comorbidities, and patient and physician expectations play a pivotal role. Treatment-free remission is a new opportunity.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results